Could a diabetes drug restore ovulation in PCOS? new trial begins

NCT ID NCT07326111

Recruiting now Disease control Sponsor: University of Bonn Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether tirzepatide, a drug already used for diabetes and weight loss, can improve irregular periods and ovulation in women with PCOS who are overweight or have obesity. About 198 women will receive either tirzepatide or a placebo for 72 weeks, along with lifestyle advice. The goal is to see if the drug helps restore normal menstrual cycles and ovulation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide
What this could lead to: If it works, this could point toward a new treatment option for PCOS-related ovarian dysfunction in women with overweight or obesity.
What could go wrong: This is a phase 4 trial, but it's still early for this specific use. The drug may not improve ovarian function, and side effects like nausea or vomiting are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT POLYCYSTIC OVARY SYNDROME (PCOS)

Contacts and locations

Locations

University Hospital BG Bergmannsheil Bochum General internal medicine, endocrinology and diabetology, gastroenterology and hepatology
ENROLLING_BY_INVITATION

Bochum, 44789, Germany
University Hospital Bonn Division of Endocrinology, Diabetes and Metabolism
RECRUITING

Bonn, 53127, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.